Mpox-Specific Neutralizing Antibodies up to 9 Months Following 1 or 2 Doses of Intradermal MVA-BN Vaccination in Sweden
This study assessed clade IIb monkeypox virus-specific antibody kinetics up to 9 months following intradermal vaccination for mpox, considering previous smallpox vaccination and human immunodeficiency virus status. Neutralizing antibodies waned significantly at 3 and 9 months, in line with previous reports of antibody waning after subcutaneous vaccination. Booster dosing and immunological memory need further study.
Authors
- Finn Filén
- Victor Westergren
- Wanda Christ (ORCID: https://orcid.org/0000-0003-3886-5248)
- Jonas Klingström (ORCID: https://orcid.org/0000-0001-9076-1441)
- Klara Sondén (ORCID: https://orcid.org/0000-0003-1585-8475)
- Carmen Espinosa‐Gongora (ORCID: https://orcid.org/0000-0002-9536-0548)
- Sara Gredmark‐Russ (ORCID: https://orcid.org/0000-0002-2446-4323)
- Anna Mia Ekström (ORCID: https://orcid.org/0000-0002-3912-1171)
- Claudia Eichler-Jonsson
- Elisabet Storgärd
- Kari Johansen
- Núria Mayola Danés
Institutions
- Linköping University (SE)
- Public Health Agency of Sweden (SE)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
- Integrated Cardio Metabolic Centre (SE)
- European Centre for Disease Prevention and Control (SE)
- Umeå University (SE)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1093/ofid/ofaf657
- Citations
- 1
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 1.04